Oscar Health, Inc. OSCR R2KR3KPHARMA
Company Overview
Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healthcare system; Campaign Builder platform, an engagement and recommendation platform for providers and payors; and reinsurance products. In addition, the company offers brokerage services and enrollment platform for brokers and consumers to shop, buy, and enroll in medical and supplemental health products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.
Why Investors Should Care
Generates a return on equity of 34.3%, reflecting efficient use of shareholder capital.
Revenue has grown at a 41.6% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.23.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $11.70B (+27.5% YoY); net profit $-443.15M.
- Trailing 12 Months Year-on-year growth — revenue +70.4%, earnings -1842.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 41.6%, profit CAGR 9.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 41.55% |
| 1 Year: | 70.40% |
Compounded Profit Growth
| 5 Years: | 8.97% |
| 1 Year: | -1,842.49% |
Stock Price Performance
| 1 Year: | +123.17% |
| 6 Months: | +102.80% |
| 3 Months: | +18.20% |
| 1 Month: | +9.14% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)55.62 · Neutral
P/E of 25.63 is above the sector median of 25.61 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 34.3%.
- Compounding revenue at 41.6% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OSCR Oscar Health, Inc. R2KR3KPHARMA | 33.32 | 25.63 | $9.11B | 0.00% | -28.69% | 34.26% | 41.55% | 8.97% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 341.00K | 353.00K | 1.55M | 18.49M | 20.45M | 19.42M | 5.00M | 5.08M | 5.54M | 5.63M | 5.23M | 4.90M | 4.33M | 6.50M | 8.80M | 5.72M | 6.09M |
| Operating Income | -95.95M | -39.35M | -80.13M | -64.04M | -72.51M | -211.68M | -68.53M | -106.49M | -192.37M | -25.36M | -6.53M | -58.24M | 185.56M | 67.81M | -48.37M | 297.12M | -230.48M | -129.25M | 704.09M | 388.63M |
| Net Income | -96.88M | -40.94M | -79.13M | -88.88M | -73.32M | -211.48M | -75.15M | -112.16M | -192.91M | -39.77M | -15.53M | -65.40M | 177.37M | 56.21M | -54.60M | 275.27M | -228.36M | -137.45M | 679.00M | 361.81M |
| Diluted EPS | -3.36 | -1.42 | -2.72 | -1.00 | -0.35 | -1.02 | -0.36 | -0.53 | -0.91 | -0.18 | -0.07 | -0.29 | 0.62 | 0.20 | -0.22 | 0.92 | -0.89 | -0.53 | 2.07 | 1.10 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 488.19M | 0 | - | 4.13B | 5.86B | 9.18B | 11.70B |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - |
| Operating Income | -259.39M | -402.27M | - | -587.45M | -242.70M | 57.16M | -419.70M |
| EBITDA | - | - | - | - | - | - | - |
| Interest Expense | - | - | - | 22.62M | 24.60M | 23.73M | 17.60M |
| Pretax Income | - | - | - | -610.08M | -267.30M | 33.43M | -437.30M |
| Tax Provision | - | - | - | -523.00K | 3.29M | 7.30M | 5.61M |
| Net Income | -261.18M | -406.82M | - | -606.27M | -270.73M | 25.43M | -443.15M |
| Diluted EPS | -9.06 | -14.16 | - | -2.85 | -1.22 | 0.10 | -1.69 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 2.27B | 3.32B | 4.53B | 3.60B | 4.84B | 6.33B |
| Total Equity | 0 | -1.30B | 1.39B | 890.38M | 803.97M | 1.01B | 977.65M |
| Cash & Equivalents | 336.64M | 826.33M | 1.10B | 1.56B | 1.87B | 1.53B | 2.77B |
| Long Term Debt | - | 142.49M | 0 | 298.00M | 298.78M | 299.56M | 430.10M |
| Total Liabilities | - | 1.82B | 1.93B | 3.63B | 2.80B | 3.82B | 5.34B |
| Current Liabilities | - | 1.67B | 1.85B | 3.26B | 2.43B | 3.46B | 4.86B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -165.37M | 222.73M | - | 380.35M | -272.16M | 978.19M | 1.09B |
| Investing Cash Flow | 150.51M | -344.71M | - | -226.52M | 577.19M | -1.39B | -241.06M |
| Financing Cash Flow | -2.12M | 611.71M | - | 301.11M | 6.45M | 68.39M | 399.21M |
| Capital Expenditure | - | - | - | -29.01M | -25.58M | -27.90M | -36.37M |
| Free Cash Flow | - | - | - | 351.34M | -297.74M | 950.30M | 1.06B |
| Net Change in Cash | - | - | - | 454.94M | 311.47M | -340.85M | 1.25B |
| Share Buybacks | 2.99M | 0 | 0 | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -53.1% | - | - | -14.2% | -4.1% | 0.6% | -3.6% |
| Net Margin % | -53.5% | - | - | -14.7% | -4.6% | 0.3% | -3.8% |
| ROE % | - | 31.4% | - | -68.1% | -33.7% | 2.5% | -45.3% |
| ROCE % | - | -66.3% | - | -46.5% | -20.7% | 4.2% | -28.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.53% | 20.59M | $687.00M |
| 2 | T. Rowe Price Investment Management, Inc. | 4.77% | 13.04M | $434.99M |
| 3 | Shaw D.E. & Co., Inc. | 4.62% | 12.64M | $421.92M |
| 4 | Vanguard Portfolio Management LLC | 4.03% | 11.03M | $368.05M |
| 5 | Vanguard Capital Management LLC | 3.87% | 10.58M | $353.04M |
| 6 | American Century Companies Inc | 3.31% | 9.06M | $302.17M |
| 7 | Jane Street Group, LLC | 2.33% | 6.37M | $212.40M |
| 8 | Thrive Capital Management, LLC | 2.32% | 6.34M | $211.69M |
| 9 | Geode Capital Management, LLC | 2.13% | 5.82M | $194.19M |
| 10 | State Street Corporation | 2.12% | 5.80M | $193.59M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OSCR
Oscar Health, Inc. (OSCR) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPZFJOLUNWN2I0bTdlckxPT18xbl9DSXpwb0RqUmVlak5pUXA0SGJRZUFVa1EzTUlydUNzdFVpZjNoZW9lUkRIMDg4RV9Mc1dSb3J4VTl4NnRsT2hNWFhjQjd0d0kxa3ZTOHltenN1Qkh6dnJ3TG5aQXZwMkxVX1FvUXl6Q0swNUhpemJuUW…
A Look at Oscar Health Inc (OSCR) After 3.4% Gain -- GF Value $2 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQNUdxa1NMQ3FDdkU4YmpYd1JDQUxvN1R3RXJqTlozamU1LXd1SGpLLUdiU3BiRlhzZV94cTFwZ1hCZUVHRVNDVTB5REk0NDltSFlqeEVrRUFnRkhpUlc2eXJqQlUtU1ZuR1dRc1Jja1ZuSVJVYzZRUzRzWWphY3R6WUE0Q2pBRURzamhGOD…
3 Big Reasons to Love Oscar Health (OSCR) - TradingView
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQQWwwMGktY0p2UFVKZ3NpeXhLdWtrQUF5ZjZ5WFBISDdjMHZJbnFXVUhuY0hiSk9ueTJWN2dfN2xfYUJDcWdkUmk1Q0puOXR2XzVHMTFtZkZRV0VGT2FEdHBYQmxoSVhZa29NMDhiU1ZEWmJMRGZBUElYajBmYk9wNEh0Z3RIcmtnTkJmaG…
584,818 Oscar Health, Inc. $OSCR Shares Bought by Halter Ferguson Financial Inc. - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPMFNEazlZWUNlYnJma3ZKUlJGdFRFV2VCTnhHeHVwTlo4dWFodTVuX3BLRFZ2OE1ENnJEMTdyb1d4NU03cVhieTg2Mlo1bjI5aEtZUDN0RmhYVVlqNEV1SEs5VDhNaEw1TEl3UW9LWEM3ejB0eVdBbmxnTlJwbURBVk5odVM1cmRGT29tdm…
Oscar Health Stock Sinks Amid This Second-Half Risk - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQbGRLcVIzbFA2anRVeEk2YzlybGZ6OTNNQ0xzQ3NhTzZsLTUwWHlHOGoxNUZTTG1SM3c4a0hPMlM4LUFLOGNtNFIyRnVmbTRteXE2MTQ1VHI1QzVNNTBEZ20tX0MtSkhvQnFjQ3hCbGRWaHQwVmZQclFLQmhhTWRGcXh6MU5CWlg5NG9FYl…
Oscar Health (OSCR) Stock May Be Undervalued Following Raised 2026 Outlook - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOUGVxa1dfaTY5QVRidkZHcTlaYWlhR0FLNFl6cWs4R0pUN2dwTzVxOXdSMkpxam14NzlpbFdWWXM5N3o0TzJ6bnlxTlNzeWtfT1h3VWpqT0lPS3k2TmgzVGVZQUtlMTE5aHBUOXZGWW5hV1ZwTjlTN3Fsd3NyQ1ZRcGpkVU5MY0VjcGh4U1…
OSCR — Frequently Asked Questions
What is the current share price of Oscar Health, Inc. (OSCR)?
As of 2026-10-22 16:30 PDT, Oscar Health, Inc. (OSCR) trades at $33.32 on NYSE. Its 52-week range is $10.85 to $34.32.
What is the market capitalisation of OSCR?
Oscar Health, Inc. (OSCR) has a market capitalisation of $9.11B on NYSE.
What is the P/E ratio of OSCR?
OSCR trades at a trailing price-to-earnings (P/E) ratio of 25.63. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 4.83.
What is the return on equity (ROE) of OSCR?
OSCR has a return on equity (ROE) of 34.26%. Its return on capital employed (ROCE) is -28.69%.
Is OSCR a good stock to buy?
This page provides a data-driven analysis of Oscar Health, Inc. (OSCR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.